Salarius Pharmaceuticals (SLRX) Stock Price, News & Analysis

Company Overview

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.

Key Stats

• Today's Range: $1.28 to $1.60
• 50-Day Range: $1.22 to $2.01
• 52-Week Range: $1.22 to $7.20
• Volume: 321,300 shs
• Average Volume: 714,326 shs
• Market Capitalization: $2.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SLRX Stock Analysis - Frequently Asked Questions

How have SLRX shares performed this year?

Salarius Pharmaceuticals' stock was trading at $5.20 on January 1st, 2024. Since then, SLRX stock has decreased by 70.2% and is now trading at $1.55.
View the best growth stocks for 2024 here.

How were Salarius Pharmaceuticals' earnings last quarter?

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) posted its quarterly earnings data on Friday, August, 9th. The company reported ($2.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($53.60) by $51.23.

When did Salarius Pharmaceuticals' stock split?

Salarius Pharmaceuticals's stock reverse split on Monday, June 17th 2024. The 1-8 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

How do I buy shares of Salarius Pharmaceuticals?

Shares of SLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Salarius Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Salarius Pharmaceuticals investors own include Bionano Genomics (BNGO), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Meta Platforms (META), T2 Biosystems (TTOO), NIO (NIO) and VBI Vaccines (VBIV).

Company Calendar

• Last Earnings: 8/09/2024
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SLRX
• CUSIP: N/A
• CIK: 1615219
• Web: www.salariuspharma.com
• Phone: (832) 834-6992
• Fax: N/A
• Employees: 20
• Year Founded: 2011

Profitability

• EPS (Most Recent Fiscal Year): ($8.17)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-12,540,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -140.28%
• Return on Assets: -105.76%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.09
• Quick Ratio: 4.09

Sales & Book Value

• Annual Sales: $1.84 million
• Price / Sales: 1.21
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.74 per share
• Price / Book: 0.14

Miscellaneous

• Outstanding Shares: 1,441,000
• Free Float: 1,421,000
• Market Cap: $2.23 million
• Optionable: Not Optionable
• Beta: 0.92